Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin

Clin Infect Dis. 2011 Jan 1;52(1):94-6. doi: 10.1093/cid/ciq072.

Abstract

Mycobacterium ulcerans infection is responsible for severe skin lesions in sub-Saharan Africa. We enrolled 30 Beninese patients with Buruli ulcers in a pilot study to evaluate efficacy of an oral chemotherapy using rifampicin plus clarithromycin during an 8-week period. The treatment was well tolerated, and all patients were healed by 12 months after initiation of therapy without relapse.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Aged
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / adverse effects
  • Benin
  • Buruli Ulcer / drug therapy*
  • Child
  • Child, Preschool
  • Clarithromycin / administration & dosage
  • Clarithromycin / adverse effects
  • Drug Therapy, Combination / methods
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mycobacterium ulcerans / isolation & purification*
  • Pilot Projects
  • Rifampin / administration & dosage
  • Rifampin / adverse effects
  • Treatment Outcome
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Clarithromycin
  • Rifampin